CODX vs. MGRM, EDAP, MLSS, VANI, NSPR, HYPR, OM, APYX, APT, and MDAI
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include Monogram Orthopaedics (MGRM), Edap Tms (EDAP), Milestone Scientific (MLSS), Vivani Medical (VANI), InspireMD (NSPR), Hyperfine (HYPR), Outset Medical (OM), Apyx Medical (APYX), Alpha Pro Tech (APT), and Spectral AI (MDAI). These companies are all part of the "medical equipment" industry.
Co-Diagnostics vs.
Monogram Orthopaedics (NASDAQ:MGRM) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability.
0.4% of Monogram Orthopaedics shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 28.1% of Monogram Orthopaedics shares are owned by company insiders. Comparatively, 6.1% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Co-Diagnostics received 271 more outperform votes than Monogram Orthopaedics when rated by MarketBeat users. However, 100.00% of users gave Monogram Orthopaedics an outperform vote while only 62.90% of users gave Co-Diagnostics an outperform vote.
Monogram Orthopaedics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -563.93%. Co-Diagnostics' return on equity of -54.94% beat Monogram Orthopaedics' return on equity.
Monogram Orthopaedics has higher earnings, but lower revenue than Co-Diagnostics. Monogram Orthopaedics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Co-Diagnostics had 4 more articles in the media than Monogram Orthopaedics. MarketBeat recorded 4 mentions for Co-Diagnostics and 0 mentions for Monogram Orthopaedics. Co-Diagnostics' average media sentiment score of 1.41 beat Monogram Orthopaedics' score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.
Monogram Orthopaedics has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.84, indicating that its stock price is 184% less volatile than the S&P 500.
Monogram Orthopaedics presently has a consensus target price of $4.00, suggesting a potential upside of 66.67%. Co-Diagnostics has a consensus target price of $1.50, suggesting a potential upside of 92.31%. Given Co-Diagnostics' higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than Monogram Orthopaedics.
Summary
Monogram Orthopaedics beats Co-Diagnostics on 10 of the 19 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CODX) was last updated on 1/5/2025 by MarketBeat.com Staff
